Entries by Russell Radefeld

Kindred Biosciences Announces Third Quarter 2018 Financial Results

San Francisco, CA (November 7, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the third quarter 2018, KindredBio reported net product revenues of $0.6 million and […]

Event: Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Tuesday, October 30, 2018 Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Telephone Dial in: toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally Conference ID:7047158 For more information about this event, please see the press release.

Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent

Statistically significant reduction in pruritus versus placebo was achieved across all dose groups. Canine atopic dermatitis is a large and growing market, and KindredBio has a broad portfolio of biologics in development to treat this condition. San Francisco, CA (October 30, 2018) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving […]

Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President

San Francisco, CA (October 23, 2018) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio, has been elected to its Board of Directors and promoted to President. Since co-founding KindredBio in 2012, Ms. […]

Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

SAN FRANCISCO, August 21, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York at the New York Marriott East Side. Denise Bevers, Co-Founder and Chief Operating Officer, will be […]

Kindred Biosciences Announces Second Quarter 2018 Financial Results

San Francisco, CA (August 9, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2018 and provided updates on its programs. “We are encouraged so far by the response from veterinarians, distributors, and cat […]